top of page

A deep dive into the oncology target PRMT5 with the CEO of Tango Therapeutics

Barbara Weber walks us through the science of PRMT5, shares her reaction to recent data, and describes how programs are designed differently.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page